Abstract
Background
Necroptosis has been linked to the development of tumors. Long non-coding RNAs (IncRNAs) have been identified as having a major role in numerous biological and pathological procedures. Despite this, the precise role that necroptosis-related lncRNAs (NRLs) have in cervical cancer (CC) and their potential for predicting its prognosis is still to a large extent unclear.
Methods
Gene expression RNA-sequencing data, mutational data, and clinical profiles for 309 CC patients were obtained from the Cancer Genome Atlas (TCGA) database. The NRLs were then identified with Pearson correlation analysis followed by splitting of the patients into training and validation sets in a 3:2 ratio. Cox and LASSO regression models were performed to construct a cervical cancer prognostic signature based on NRLs. This 5-NRLs signature was then verified by Kaplan–Meier survival analysis, receiver operating characteristic (ROC) curve, and nomogram for prognostic prediction. Further, a correlation study between the risk score (RS) and immune cell infiltration, immune checkpoint molecules, tumor mutation burden (TMB), and the sensitivity of chemotherapy drug was conducted. To validate the 5-NRLs, a quantitative reverse transcription polymerase chain reaction (qRT-PCR) was finally performed.
Results
The 5-NRLs signature was designed to accurately predict the prognosis of CC. It consists of AC092153.1, AC007686.3, LINC01281, AC009097.2, and RUSC1-AS1 and was found to be highly predictive using ROC and Kaplan–Meier curves. Furthermore, when analyzed through stratified survival analysis, it was confirmed to be an independent risk factor for prognosis. The nomogram and calibration curves further validated its clinical utility. Moreover, distinct differences between two risk groups were observed when examining immune cell infiltration, immune checkpoint molecules, somatic gene alterations and half-inhibitory concentration of anticancer drug.
Conclusions
The 5-NRLs signature is a novel and valuable tool for evaluating the prognosis of CC patients, providing clinicians with an informed decision-making framework to formulate tailored treatment plans for their patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The data used to support the findings of this study are available from the corresponding author upon request.
Code availability
Not applicable.
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492
Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, Peters S (2019) Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol 30(1):44–56. https://doi.org/10.1093/annonc/mdy495
Chen Q, Hu L, Huang D, Chen K, Qiu X, Qiu B (2020a) Six-lncRNA immune prognostic signature for cervical cancer. Front Genet 11:533628. https://doi.org/10.3389/fgene.2020.533628
Chen YA, Cheng L, Zhang Y, Peng L, Yang HG (2020b) LncRNA RUSC1-AS1 promotes the proliferation of hepatocellular carcinoma cells through modulating NOTCH signaling. Neoplasma 67(6):1204–1213. https://doi.org/10.4149/neo_2020_191010N1024
Christofferson DE, Yuan J (2010) Necroptosis as an alternative form of programmed cell death. Curr Opin Cell Biol 22(2):263–268. https://doi.org/10.1016/j.ceb.2009.12.003
Dimitriou F, Staeger R, Ak M, Maissen M, Kudura K, Barysch MJ, Levesque MP, Cheng PF, Dummer R, Mangana J (2021) Frequency treatment and outcome of immune-related toxicities in patients with immune-checkpoint inhibitors for Advanced melanoma: results from an institutional database analysis. Cancers (Basel). https://doi.org/10.3390/cancers13122931
Du X, Pu X, Wang X, Zhang Y, Jiang T, Ge Y, Zhu H (2022) A novel necroptosis-related lncRNA based signature predicts prognosis and response to treatment in cervical cancer. Front Genet 13:938250. https://doi.org/10.3389/fgene.2022.938250
Fan Y, Sheng W, Meng Y, Cao Y, Li R (2020) LncRNA PTENP1 inhibits cervical cancer progression by suppressing miR-106b. Artif Cells Nanomed Biotechnol 48(1):393–407. https://doi.org/10.1080/21691401.2019.1709852
Fang Y, Fullwood MJ (2016) Roles, functions, and mechanisms of long non-coding RNAs in cancer. Genom Proteom Bioinform 14(1):42–54. https://doi.org/10.1016/j.gpb.2015.09.006
Gong Y, Fan Z, Luo G, Yang C, Huang Q, Fan K, Cheng H, Jin K, Ni Q, Yu X, Liu C (2019) The role of necroptosis in cancer biology and therapy. Mol Cancer 18(1):100. https://doi.org/10.1186/s12943-019-1029-8
Grootjans S, Vanden BT, Vandenabeele P (2017) Initiation and execution mechanisms of necroptosis: an overview. Cell Death Differ 24(7):1184–1195. https://doi.org/10.1038/cdd.2017.65
Jia H, Hao S, Cao M, Wang L, Bai H, Shui W, Yang X (2022) m (6)A-related lncRNAs are potential prognostic biomarkers of cervical cancer and affect immune infiltration. Dis Markers 2022:8700372. https://doi.org/10.1155/2022/8700372
Li Y, Chen Z, Wu L, Ye J, Tao W (2020) Cellular heterogeneity map of diverse immune and stromal phenotypes within breast tumor microenvironment. PeerJ 8:e9478. https://doi.org/10.7717/peerj.9478
Lin Z, Zou J, Sui X, Yao S, Lin L, Wang J, Zhao J (2022) Necroptosis-related lncRNA signature predicts prognosis and immune response for cervical squamous cell carcinoma and endocervical adenocarcinomas. Sci Rep 12(1):16285. https://doi.org/10.1038/s41598-022-20858-5
Liu Y, Yang Y, Li L, Liu Y, Geng P, Li G, Song H (2018) LncRNA SNHG1 enhances cell proliferation, migration, and invasion in cervical cancer. Biochem Cell Biol 96(1):38–43. https://doi.org/10.1139/bcb-2017-0188
Luan X, Wang Y (2018) LncRNA XLOC_006390 facilitates cervical cancer tumorigenesis and metastasis as a ceRNA against miR-331–3p and miR-338–3p. J Gynecol Oncol 29(6):e95. https://doi.org/10.3802/jgo.2018.29.e95
Mohanty S, Yadav P, Lakshminarayanan H, Sharma P, Vivekanandhan A, Karunagaran D (2022) RETRA induces necroptosis in cervical cancer cells through RIPK1, RIPK3, MLKL and increased ROS production. Eur J Pharmacol 920:174840. https://doi.org/10.1016/j.ejphar.2022.174840
Moujalled DM, Cook WD, Murphy JM, Vaux DL (2014) Necroptosis induced by RIPK3 requires MLKL but not Drp1. Cell Death Dis 5(2):e1086. https://doi.org/10.1038/cddis.2014.18
Noy R, Pollard JW (2014) Tumor-associated macrophages: from mechanisms to therapy. Immunity 41(1):49–61. https://doi.org/10.1016/j.immuni.2014.06.010
Pfaendler KS, Tewari KS (2016) Changing paradigms in the systemic treatment of advanced cervical cancer. Am J Obstet Gynecol 214(1):22–30. https://doi.org/10.1016/j.ajog.2015.07.022
Pisani P, Bray F, Parkin DM (2002) Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 97(1):72–81. https://doi.org/10.1002/ijc.1571
Qin X, Ma D, Tan YX, Wang HY, Cai Z (2019) The role of necroptosis in cancer: a double-edged sword? Biochim Biophys Acta Rev Cancer 1871(2):259–266. https://doi.org/10.1016/j.bbcan.2019.01.006
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O’Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823–1833. https://doi.org/10.1056/NEJMoa1606774
Rodriguez DA, Weinlich R, Brown S, Guy C, Fitzgerald P, Dillon CP, Oberst A, Quarato G, Low J, Cripps JG, Chen T, Green DR (2016) Characterization of RIPK3-mediated phosphorylation of the activation loop of MLKL during necroptosis. Cell Death Differ 23(1):76–88. https://doi.org/10.1038/cdd.2015.70
Schmitt AM, Chang HY (2016) Long noncoding RNAs in cancer pathways. Cancer Cell 29(4):452–463. https://doi.org/10.1016/j.ccell.2016.03.010
Seifert L, Werba G, Tiwari S, Giao LN, Alothman S, Alqunaibit D, Avanzi A, Barilla R, Daley D, Greco SH, Torres-Hernandez A, Pergamo M, Ochi A, Zambirinis CP, Pansari M, Rendon M, Tippens D, Hundeyin M, Mani VR, Hajdu C, Engle D, Miller G (2016) The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. Nature 532(7598):245–249. https://doi.org/10.1038/nature17403
Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, Bajorin DF, Reuter VE, Herr H, Old LJ, Sato E (2007) CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A 104(10):3967–3972. https://doi.org/10.1073/pnas.0611618104
Steller MA (2002) Cervical cancer vaccines: progress and prospects. J Soc Gynecol Investig 9(5):254–264. https://doi.org/10.1016/s1071-5576(02)00166-1
Strilic B, Yang L, Albarrán-Juárez J, Wachsmuth L, Han K, Müller UC, Pasparakis M, Offermanns S (2016) Tumour-cell-induced endothelial cell necroptosis via death receptor 6 promotes metastasis. Nature 536(7615):215–218. https://doi.org/10.1038/nature19076
Tang D, Kang R, Berghe TV, Vandenabeele P, Kroemer G (2019) The molecular machinery of regulated cell death. Cell Res 29(5):347–364. https://doi.org/10.1038/s41422-019-0164-5
Tao S, Tao K, Cai X (2022) Necroptosis-associated lncRNA prognostic model and clustering analysis: prognosis prediction and tumor-infiltrating lymphocytes in breast cancer. J Oncol 2022:7099930. https://doi.org/10.1155/2022/7099930
Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Stehman FB, Brady MF, Burger RA, Thigpen JT, Birrer MJ, Waggoner SE, Moore DH, Look KY, Koh WJ, Monk BJ (2017) Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 390(10103):1654–1663. https://doi.org/10.1016/S0140-6736(17)31607-0
Tong CJ, Deng QC, Ou DJ, Long X, Liu H, Huang K (2021) LncRNA RUSC1-AS1 promotes osteosarcoma progression through regulating the miR-340–5p and PI3K/AKT pathway. Aging (Albany, NY) 13(16):20116–20130. https://doi.org/10.18632/aging.203047
van Dijk N, Funt SA, Blank CU, Powles T, Rosenberg JE, van der Heijden MS (2019) The cancer immunogram as a framework for personalized immunotherapy in urothelial cancer. Eur Urol 75(3):435–444. https://doi.org/10.1016/j.eururo.2018.09.022
Wang Q, Steger A, Mahner S, Jeschke U, Heidegger H (2019) The formation and therapeutic update of tumor-associated macrophages in cervical cancer. Int J Mol Sci. https://doi.org/10.3390/ijms20133310
Wang J, Shen B, Liu X, Jiang J (2022) A novel necroptosis-related lncRNA signature predicts the prognosis and immune microenvironment of hepatocellular carcinoma. Front Genet 13:985191. https://doi.org/10.3389/fgene.2022.985191
Xing C, Sun SG, Yue ZQ, Bai F (2021) Role of lncRNA LUCAT1 in cancer. Biomed Pharmacother 134:111158. https://doi.org/10.1016/j.biopha.2020.111158
Yang G, Li Z, Dong L, Zhou F (2021) lncRNA ADAMTS9-AS1 promotes bladder cancer cell invasion, migration, and inhibits apoptosis and autophagy through PI3K/AKT/mTOR signaling pathway. Int J Biochem Cell Biol 140:106069. https://doi.org/10.1016/j.biocel.2021.106069
Zhang C, Li Z, Qi F, Hu X, Luo J (2019a) Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma. Ann Transl Med 7(22):648. https://doi.org/10.21037/atm.2019.10.84
Zhang G, Fan E, Zhong Q, Feng G, Shuai Y, Wu M, Chen Q, Gou X (2019b) Identification and potential mechanisms of a 4-lncRNA signature that predicts prognosis in patients with laryngeal cancer. Hum Genomics 13(1):36. https://doi.org/10.1186/s40246-019-0230-6
Acknowledgements
We thank the TCGA, KEGG, and GO program for kindly providing publicly available data for analysis.
Funding
The authors have not disclosed any funding.
Author information
Authors and Affiliations
Contributions
XK and YX contributed to conceptualization and writing original draft. All contributors have reviewed and approved the completed version of the article.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Ethical approval
Not applicable.
Consent to participate
Not applicable.
Consent for publication
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Kong, X., Xiong, Y. A novel necroptosis-related long non-coding RNA signature predicts prognosis and immune response in cervical cancer patients. J Cancer Res Clin Oncol 149, 12947–12964 (2023). https://doi.org/10.1007/s00432-023-05158-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-023-05158-3